Thursday, 5 November 2026European Markets

ALTRI SGPS Stock Went Down By Over 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ALTRI SGPS (PSI: ALTR.LS) fell by a staggering 17.04% in 5 sessions from €4.93 to €4.09 at 20:22 EST on Tuesday, following the last session's upward trend. PSI is jumping 0.31% to €6,113.80, after two sequential sessions in a row of gains.

ALTRI SGPS's last close was €4.97, 27.18% under its 52-week high of €6.83.

About ALTRI SGPS

Altri, SGPS, S.A. produces and sells cellulosic fibers and energy in Portugal and internationally. The company produces pulp products for various application including production of paper, tissue, and printing and writing papers; and dissolving pulp for use of textile production. It is also involved timber commercialization; forest management; production of forest-based renewable energy, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.76.

PE Ratio

ALTRI SGPS has a trailing twelve months price to earnings ratio of 5.38. Meaning, the purchaser of the share is investing €5.38 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.22%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 29.6%, now sitting on 1B for the twelve trailing months.

Moving Average

ALTRI SGPS's worth is way under its 50-day moving average of €4.82 and way below its 200-day moving average of €5.48.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 17, 2022, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 5.31%.

More news about ALTRI SGPS (ALTR.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com